• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Studies show Penthrox is superior to standard of care for acute trauma pain

Medical Developments International (MDI) has announced data from multiple European studies demonstrating the benefits of MDI’s Penthrox methoxyflurane inhaler for the treatment of pain from acute trauma.

Among the findings announced, Penthrox was shown to be superior to intravenous morphine, NSAIDS, paracetamol (acetaminophen), and ketoprofen in trauma settings; Penthrox successfully reduced pain in discolation injuries, resulting in less time spent in the emergency department; and health care professionals and patients were highly satisfied with the inhaler.

MDI CEO John Sharman commented, “We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over standard of care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication.”

MDI also announced the launch of Penthrox in Italy, which will trigger a $2 million milestone payment from Mundipharma in 2020. Mundipharm has the rights to Penthrox in most of Europe and in Australia.

Sharman said, “We are delighted to finally launch Penthrox in the important European market of Italy. There has been a number of clinical studies completed in preparation for the launch of Penthrox in Italy. In particular, a study of 272 trauma patients in 15 Italian emergency units (“MEDITA”), showed that Penthrox was superior to standard of sare, including opioids, for adult trauma pain patients in Italy. . . . Penthrox is now well placed to develop into a leading trauma pain medication in Italy and throughout Europe.”

Mundipharma Asset Lead Maya Marescotti added, “We are delighted to have launched Penthrox in Italy, to help provide fast and effective relief for adult patients experiencing trauma pain. We see this inhaled analgesic as an important medication for trauma patients here and throughout Europe and we look forward to our continued collaboration with MDI.”

Read the MDI press release on Penthrox study results.
Read the MDI press release on the Penthrox launch in Italy.

Share

published on October 25, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews